Influenza A NP (265-273) (HLA-A3)

ILRGSVAHK-acid

  • Description

  • Application Data

Description

Influenza A NP (265-273) (HLA-A3) is a CEF control peptide that is derived from Influenza A.

See full description

Application Data

Catalogue number crb1001467
Molecular Weight 979.6
Sequence (one letter code)

ILRGSVAHK-acid

Sequence (three letter code)

H-Ile-Leu-Arg-Gly-Ser-Val-Ala-His-Lys-OH

Purity >95%
Storage -20°C
References

Bauer et al (2018). Influenza Virus Mounts a Two-Pronged Attack on Host RNA Polymerase II Transcription. Cell Rep. PMID: 29768209

Taubenberger and Morens (2008). The pathology of influenza virus infections. Annu Rev Pathol. PMID: 18039138

Biswas et al (1998). Influenza virus nucleoprotein interacts with influenza virus polymerase proteins. J Virol. PMID: 9621005

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Influenza A NP (265-273) (HLA-A3) is a CEF control peptide that is derived from Influenza A. Influenza A is an enveloped negative-strand RNA virus that is capable of interfering with host transcription, which can ultimately cause cell death. The action of the virus particles decreases the downstream gene occupancy of RNA polymerase II, as well as instigating cellular stress, resulting in the failure of polymerase II termination at poly(A) sites. Influenza A NP (265-273) (HLA-A3) is defined as a CEF control peptide due to its antigenic properties. Clinically, this peptide is a suitable epitope for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-A3 refers to the cell HLA type that this peptide acts on.

The nucleoprotein (NP) is a structural protein that encapsulates the negative strand of viral RNA. NP plays a critical role in the transition of influenza virus RNA synthesis from transcription mode to replication mode.

Influenza A NP (265-273) (HLA-A3)

Cat No.Pack SizePriceQty.
0.5mg£85.00
1mg£110.00
Bulk Quote

Download Family PDF